Key result
Initiation of rivaroxaban and apixaban for venous thromboembolism increased significantly over time, reaching 70% and 16% respectively by September 2016, while VKA initiation decreased to 12%.
Population
19,578 patients with venous thromboembolism identified between February 2012 and September 2016 in Danish…
Comparison
Non-vitamin K antagonist oral anticoagulants vs Vitamin K antagonists (VKA)
Design
Cohort
Authors
Loading...
Documents rapid NOAC uptake in VTE; extends RCT evidence with registry trends yet leaves comparative effectiveness open.
Cohort (n=19,578)
Absolute Event Rate: 70% vs 12%
p-value: p=<0.001
The initiation of NOACs, particularly rivaroxaban and apixaban, has significantly increased over time for VTE treatment in Denmark, largely replacing VKAs except in patients with specific comorbidities.
Sindet‐Pedersen et al. (2017) conducted a cohort in Venous thromboembolism (n=19,578). NOACs (rivaroxaban, apixaban, dabigatran) vs. Vitamin K antagonists (VKA) was evaluated on Proportion of patients initiated on rivaroxaban vs VKA by September 2016 (p=<0.001). Initiation of rivaroxaban and apixaban for venous thromboembolism increased significantly over time, reaching 70% and 16% respectively by September 2016, while VKA initiation decreased to 12%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: